Literature DB >> 23688319

Maternal plasma soluble TRAIL is decreased in preeclampsia.

Piya Chaemsaithong1, Tinnakorn Chaiworapongsa, Roberto Romero, Steven J Korzeniewski, Tamara Stampalija, Nandor Gabor Than, Zhong Dong, Jezid Miranda, Lami Yeo, Sonia S Hassan.   

Abstract

OBJECTIVE: Preeclampsia (PE) is characterized by systemic intravascular inflammation. Women who develop PE are at an increased risk for cardiovascular disease in later life. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) has anti-atherosclerotic effects in endothelial cells and can mediate neutrophil apoptosis. Low soluble TRAIL (sTRAIL) and high C-reactive protein (CRP) concentrations are associated with an increased risk of future cardiovascular disease in non-pregnant individuals. The aim of this study was to determine whether maternal plasma concentrations of sTRAIL and CRP differ between women with PE and those with uncomplicated pregnancies.
METHOD: This cross-sectional study included women with an uncomplicated pregnancy (n = 93) and those with PE (n = 52). Maternal plasma concentrations of sTRAIL and CRP concentrations were determined by ELISA.
RESULTS: 1) The median plasma sTRAIL concentration (pg/mL) was significantly lower and the median plasma CRP concentration was significantly higher in women with PE than in those with an uncomplicated pregnancy (25.55 versus 29.17; p = 0.03 and 8.0 versus 4.1; p = 0.001, respectively); 2) the median plasma concentration sTRAIL/CRP ratio was two-fold lower in women with PE than in those with an uncomplicated pregnancy (p < 0.001); and 3) women with plasma sTRAIL and CRP ratio in the lowest quartile were 8 times more likely to have PE than women with concentrations in the upper three quartiles (OR 8.9; 95% CI: 2.8-27.8).
CONCLUSION: Maternal plasma sTRAIL concentrations are lower (while those of CRP are higher) in women with PE than in those with uncomplicated pregnancies. These findings are consistent with the evidence of intravascular inflammation in this disorder.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23688319      PMCID: PMC4100602          DOI: 10.3109/14767058.2013.806906

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  202 in total

Review 1.  The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia.

Authors:  Henning Hagmann; Ravi Thadhani; Thomas Benzing; S Ananth Karumanchi; Holger Stepan
Journal:  Clin Chem       Date:  2012-03-19       Impact factor: 8.327

Review 2.  Preeclampsia and cardiovascular risk.

Authors:  W Hermes; F Van Kesteren; C J M De Groot
Journal:  Minerva Ginecol       Date:  2012-08

3.  Plasma IL-4, IL-8, IL-12, interferon-γ and CRP levels in pregnant women with preeclampsia, and their relation with severity of disease and fetal birth weight.

Authors:  Deniz Cemgil Arikan; Murat Aral; Ayhan Coskun; Ali Ozer
Journal:  J Matern Fetal Neonatal Med       Date:  2012-01-30

4.  Association of high-sensitivity C-reactive protein serum levels in early pregnancy with the severity of preeclampsia and fetal birth weight.

Authors:  Samira Behboudi Gandevani; Lida Moghadam Banaem; Bita Mohamadi; Narges Aliyan Moghadam; Mohammad Asghari
Journal:  J Perinat Med       Date:  2012-06-14       Impact factor: 1.901

5.  An analysis of C-reactive protein, procalcitonin, and D-dimer in pre-eclamptic patients.

Authors:  Umran Kucukgoz Gulec; Fatma Tuncay Ozgunen; Ahmet Baris Guzel; Selim Buyukkurt; Gulsah Seydaoglu; Ibrahim Ferhat Urunsak; Ismail Cuneyt Evruke
Journal:  Am J Reprod Immunol       Date:  2012-07-11       Impact factor: 3.886

6.  Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period.

Authors:  Loren Petrozella; Mala Mahendroo; Brenda Timmons; Scott Roberts; Donald McIntire; James M Alexander
Journal:  Am J Obstet Gynecol       Date:  2012-06-11       Impact factor: 8.661

7.  Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia.

Authors:  Andreea G Moore; Heather Young; Jennifer M Keller; Linda R Ojo; Jing Yan; Tiffany A Moore Simas; Sharon E Maynard
Journal:  J Matern Fetal Neonatal Med       Date:  2012-08-22

8.  Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1.

Authors:  Eric M George; Joey P Granger
Journal:  Hypertension       Date:  2012-05-07       Impact factor: 10.190

Review 9.  C-reactive protein and later preeclampsia: systematic review and meta-analysis taking into account the weight status.

Authors:  Fernanda Rebelo; Michael M Schlüssel; Juliana S Vaz; Ana Beatriz Franco-Sena; Thatiana J P Pinto; Francisco I Bastos; Amanda R A Adegboye; Gilberto Kac
Journal:  J Hypertens       Date:  2013-01       Impact factor: 4.844

10.  Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.

Authors:  Sarosh Rana; Ana Sofia Cerdeira; Julia Wenger; Saira Salahuddin; Kee-Hak Lim; Steven J Ralston; Ravi I Thadhani; S Ananth Karumanchi
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

View more
  4 in total

1.  TRAIL Is Decreased Before 20 Weeks Gestation in Women with Hypertensive Disorders of Pregnancy.

Authors:  Cheng Zhou; Yan Long; Hongling Yang; Chunyan Zhu; Qingling Ma; Yonggang Zhang
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

2.  Feasibility of placenta-derived mesenchymal stem cells as a tool for studying pregnancy-related disorders.

Authors:  Naoki Fuchi; Kiyonori Miura; Hanako Doi; Tao-Sheng Li; Hideaki Masuzaki
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

3.  Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes.

Authors:  Henry Adekola; Roberto Romero; Piya Chaemsaithong; Steven J Korzeniewski; Zhong Dong; Lami Yeo; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2014-10-28

Review 4.  Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia.

Authors:  Janri Geldenhuys; Theresa Marie Rossouw; Hendrik Andries Lombaard; Marthie Magdaleen Ehlers; Marleen Magdalena Kock
Journal:  Front Immunol       Date:  2018-07-20       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.